Lupin launches authorized generic version of Duexis in the US

Ibuprofen and Famotidine Tablets (RLD: Duexis) had estimated annual sales of USD 765 million in the U.S. (IQVIA MAT July 2021).

Sep 16, 2021 10:09 IST India Infoline News Service

Lupin has announced the launch of the authorized generic version of Duexis (ibuprofen and famotidine) Tablets, 800 mg/26.6 mg, of Horizon Medicines LLC.

According to the regulatory filing, Ibuprofen and Famotidine Tablets, 800 mg/26.6 mg, are indicated for the relief of signs and symptoms of rheumatoid arthritis, osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers, which in the clinical trials was defined as a gastric and/or duodenal ulcer in patients who are taking ibuprofen for those indications.

Ibuprofen and Famotidine Tablets (RLD: Duexis) had estimated annual sales of USD 765 million in the U.S. (IQVIA MAT July 2021).

At around 10.51 AM, Lupin was trading at Rs979.35 per piece down 1.06% on Sensex. 

Related Story

Open Free Demat Account (Rs699)